Skip to main content
SpringerLink
Log in

Prophylaxe und Behandlung spezieller Nebenwirkungen von Zytostatika

  • Chapter
Book cover Praktische Aspekte der supportiven Therapie in Hämatologie und Onkologie

  • 39 Accesses

Zusammenfassung

Neben der allgemeinen, akut oder subchronisch auftretenden Toxizität auf gesundes, rasch proliferierendes Gewebe treten im Rahmen konventionell- und hochdosierter Chemotherapien — abhängig vom eingesetzten Zytostatikum — auch eine Reihe organspezifischer Toxizitäten auf. Diese lassen sich weniger durch die antiproliferative Aktivität, sondern vielmehr durch andere Eigenschaften des Zytostatikums wie der Entstehung bestimmter toxischer Metabolite oder durch relativ hohe Anreicherungen in einzelnen Organen erklären.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 69.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

Literatur zu 8.1

  • Chertow GM, Sayegh MH, llgren RL, Lazarus JM (1996) Is the administration of dopamine associated with adverse or favorable outcomes in acute renal failure? Am J Med 101: 49–53

    Article  PubMed  CAS  Google Scholar 

  • Kintzel PE, Dorr RT (1995) Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function. Cancer Treat Rev 21: 33–64

    Article  PubMed  CAS  Google Scholar 

  • Lipp H-P (1995) Prevention and management of anticancer drug toxicity — The significance of clinical pharmacokinetics. Univ.-Verlag, Jena

    Google Scholar 

  • Skinner R (1995) Strategies to prevent nephrotoxicity of anticancer drugs. Curr Opin Oncol 7: 310–315

    Article  PubMed  CAS  Google Scholar 

  • Thadhani R, Pascual M, Bonventre JV (1996) Acute Renal Failure. N Engl J Med 30: 1448–1459

    Article  Google Scholar 

Literatur zu 8.2

  • Alberts DS, Noel JK (1995) Cisplatin-associated neurotoxicity: Can it be prevented? Anti-Cancer Drugs 6: 369

    Article  PubMed  CAS  Google Scholar 

  • Anand AJ, Bashey B (1993) Newer insights into cisplatin nephrotoxicity. Ann Pharmacother 27: 1519–1525

    PubMed  CAS  Google Scholar 

  • Bokemeyer C, Fels LM, Dunn T et al. (1996) Silibinin protects against cisplatin-induced nephrotoxicity without compromising cisplatin or ifosphamide anti-tumour activity. Br J Cancer 74: 2036–2041

    Article  PubMed  CAS  Google Scholar 

  • Bokemeyer C, Hartmann JT, Kanz L (1997) Prävention cisplatininduzierter Chemotherapietoxizitäten durch Amifostin. Arzt Krankenh 2: 52–56

    Google Scholar 

  • McKeage MJ (1995) Comparative adverse effect profiles of platinum drugs. Drug Saf 13: 228–244

    Article  PubMed  CAS  Google Scholar 

Literatur zu 8.3

  • Bedi A, Miller CB, Hanson JL et al. (1995) Association of BK virus with failure of prophylaxis against cystitis following bone marrow transplantation. J Clin Oncol 13: 1103–1109

    PubMed  CAS  Google Scholar 

  • Dechant KL, Brogden RN, Pilkington T, Faulds D (1991) Ifosfamide/Mesna: A review of its antineoplastic activity, pharmacokinetic properties and therapeutic efficacy in cancer. Drugs 42: 428–467

    Article  PubMed  CAS  Google Scholar 

  • Fleming RA, Cruz JM, Webb CD et al. (1996) Urinary elimination of cyclophosphamide alkylating metabolites and free thiols following two administration schedules of high-dose cyclophosphamide and mesna. Bone Marrow Transplant 17: 497–501

    PubMed  CAS  Google Scholar 

  • Haselberger MB, Schwinghammer TL (1995) Efficacy of mesna for prevention of hemorrhagic cystitis after high-dose cyclophosphamide therapy. Ann Pharmacother 29: 918–921

    PubMed  CAS  Google Scholar 

  • Katz A, Epelman S, Anelli A et al. (1995) A prospective randomized evaluation of three schedules of mesna administration in patients receiving an ifosfamide-containing chemotherapy regimen: sustained efficiency and simplified administration. J Cancer Res Clin Oncol 121: 128–131

    Article  PubMed  CAS  Google Scholar 

  • Kurowski V, Wagner T (1997) Urinary excretion of ifosfamide, 4-hydroxyifosfamide, 3- and 2-dechloro-ethylifosfamide, mesna, and dimesna in patients on fractionated intravenous ifosfamide and concomitant mesna therapy. Cancer Chemother Pharmacol 39: 431–439

    Article  PubMed  CAS  Google Scholar 

  • Lauterburg BH, Nguyen T, Hartmann B et al. (1994) Depletion of total cysteine, glutathione, and homocysteine in plasma by ifofamide/mesna therapy. Cancer Chemother Pharmacol 35: 132–136

    Article  PubMed  CAS  Google Scholar 

Literatur zu 8.4

  • Borsi JD, Sagen ES, Romslo I, Moe PJ (1990) Rescue after intermediate and high-dose Methotrexate. Ped Hematol Oncol 7: 347–363

    Article  CAS  Google Scholar 

  • Comelia P, Palmieri G, Beneduce G et al. (1996) Significance of methotrexate serum level achieved in patients with gastroinstestinal malignancies treated with sequential methotrexate, L-Folinic Acid and 5-Fluorouracil. Oncology 53: 198–203

    Article  Google Scholar 

  • Gögbuget N, Hoelzer D (1996) High-dose methotrexate in the treatment of adult acute lymphoblastic leukemia. Ann Hematol 72: 194–201

    Article  Google Scholar 

  • Relling MV, Stapleton F, Ochs J et al. (1988) Removal of methotrexate, leucovorin and their metabolites by combined hemodialysis and hemoperfusion. Cancer 62: 884–888

    Article  PubMed  CAS  Google Scholar 

  • Relling MV, Fairclough D, Ayers D et al. (1994) Patient characteristics associated with high-risk methotrexate concentrations and toxicity. J Clin Oncol 12: 1667–72

    PubMed  CAS  Google Scholar 

  • Teresi ME, Rodman JH (1993) Methotrexate; in: Clinical phamacokinetics pocket reference; J.E. Murphy (ed), 157–177. American Society of Hospital Pharmacists

    Google Scholar 

  • Thomson AH, Daly M, Knepil J, Harden P, Symonds P (1996) Methotrexate removal during haemodi-alysis in a patient with advanced laryngeal carcinoma. Cancer Chemother Pharmacol 38: 566–570

    Article  PubMed  CAS  Google Scholar 

  • Treon SP, Chabner BA (1996) Concepts in use of high-dose methotrexate therapy. Clin Chem 42: 1322–1329

    PubMed  CAS  Google Scholar 

Literatur zu 8.5

  • Bizzari JP, Le Bail N (1994) Docetaxel: RP 56976. Integrated safety summary, updated analysis. Rhone-Poulenc Rorer, 25 October 1994

    Google Scholar 

  • Boehm DK (1996) Paclitaxel. Premedication regimens. J Natl Cancer Inst 88: 463–465

    Article  PubMed  CAS  Google Scholar 

  • Bristol-Meyers Squibb (1993) Paclitaxel administration guide. Princeton/NJ

    Google Scholar 

  • Chan S, Winterbottom L, Gardner S (1996) Response to dexamethasone in patients with fluid retention after docetaxel. Lancet 347: 1486–1487

    Article  PubMed  CAS  Google Scholar 

  • Gennari A, Salvadori B, Tognoni A, Conte PF (1996) Rapid intravenous premedication with dexamethasone prevents hypersensitivity reactions to paclitaxel. Ann Oncol 7: 978–979

    PubMed  CAS  Google Scholar 

  • Parikh B, Khanolkar S, Advani SH (1996) Safety profile of single-dose dexamethasone premedication for paclitaxel. J Clin Oncol 14: 2189–2190

    PubMed  CAS  Google Scholar 

  • Piccard MJ, Klijn J, Paridaens R et al. (1997) Corticosteroids significantly delay the onset of docetaxel-induced fluid-retention: Final results of a randomized study of the european organization for research and treatment of cancer investigational drug branch for breast cancer. J Clin Oncol 15: 3149–3155

    Google Scholar 

  • Riva A, Fumoleau P, Roché H et al. (1997) Efficacy and safety of different corticosteroid (C) premedications (P) in breast cancer (BC) patients (Pts) treated with Taxotere (T). Proc Am Soc Clin Oncol 16: 188 a

    Google Scholar 

  • Weiss RB, Donehower RC, Wienik PH et al. (1990) Hypersensitivity reactions from paclitaxel. J Clin Oncol 8: 1263–1268

    PubMed  CAS  Google Scholar 

Literatur zu 8.6

  • Alberts DS, Bleyer WA (1996) Future development of amifostine in cancer treatment. Semin Oncol 23 Suppl 8: 90–99

    Google Scholar 

  • Bokemeyer C, Hartmann JT, Fels L et al. (1997) Amifostine protects against early cisplatin-induced renal damage and enhances CD 34+ cell numbers for PBSC collection. Proc Am Soc Clin Oncol 16: 47 a/166 (Abstr)

    Google Scholar 

  • Bokemeyer C, Hartmann JT, Kanz L (1997) Prävention cisplatininduzierter Chemotherapietoxizitäten durch Amifostin. Arzt Krankenh 2: 52–56

    Google Scholar 

  • Capizzi RL, Oster W (1995) Protection of normal tissue from the cytotoxic effects of chemotherapy and radiation by amifostine: clinical experiences. Eur J Cancer 31 A (Suppl 1): 8–13

    Article  Google Scholar 

  • Dorr RT (1996) Cytoprotective agents for anthracyclines. Semin Oncol 23 (Suppl 8): 23–34

    PubMed  CAS  Google Scholar 

  • Gerritsen-Van der Hoop R, Hamers FP, Neijt JP, Veldman H, Gispen WH, Jennekens FG (1994) Protection against cisplatin induced neurotoxicity by ORG 2766: histological and electrophysiological evidence. J Neurol Sci 126: 109–115

    Article  PubMed  CAS  Google Scholar 

  • Hamers FP, Pette C, Neijt JP, Gispen WH (1993) The ACTH-(4–9) analog, ORG 2766 prevents taxol-induced neuropathy in rats. Eur J Pharmacol 233: 177–178

    Article  PubMed  CAS  Google Scholar 

  • Hellmann K (1996) Anthracycline cardiotoxicity prevention by dexrazoxane: breakthrough of a barrier-sharpens antitumor profile and therapeutic index. J Clin Oncol 14: 332–333

    PubMed  CAS  Google Scholar 

  • Highley MS, Momerency G, van Cuwenberghe K (1995) Formation of chloroethylamine and 1,3-oxazolidine-2-one following ifosfamide. administration in humans. Drug Metab Dispos 23: 433–437

    PubMed  CAS  Google Scholar 

  • Hochster H, Wasserheit C, Speyer J (1995) Cardiotoxicity and cardioprotection during chemotherapy. Curr Opin Oncol 7: 304–309

    Article  PubMed  CAS  Google Scholar 

  • Imondi AR, Delia-Torre P, Mazue G et al. (1996) Dose-response relationship of dexrazoxane for prevention of doxorubicin-induced cardiotoxicity in mice, rats, and dogs. Cancer Res 56: 4200–4204

    PubMed  CAS  Google Scholar 

  • Kemp G, Rose P,Lurain J et al. (1996) Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. J Clin Oncol 14: 2101–2112

    PubMed  CAS  Google Scholar 

  • Küpfer A, Aeschlimann C, Cerny C (1996) Methylenblue and the neurotoxic mechanism of ifosfamide encephalopathy. Eur J Clin Pharmacol zz: 249–252

    Google Scholar 

  • Schiller JH, Storer B, Berlin J et al. (1996) Amifostine, cisplatin, and vinblastine in metastatic non-small-cell lung cancer: a report of high response rates and prolonged survival J ClinOncol 14: 1913–1921

    CAS  Google Scholar 

  • Shan K, Lincoff AM, Young JB (1996) Anthracycline-induced cardiotoxicity. Ann Intern Med 125: 47–58

    PubMed  CAS  Google Scholar 

  • Swain SM, Whaley FS, Gerber MC, Ewer MS, Bianchine JR, Gams RA (1997) Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy. J Clin Oncol 15: 1333–1340

    PubMed  CAS  Google Scholar 

  • Swain SM, Whaley FS, Gerber MC et al. (1997) Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J Clin Oncol 15: 1318–1332

    PubMed  CAS  Google Scholar 

  • Tannehill SP,Mehta MP (1996) Amifostine and radiation therapy: past, present, and future. Semin Oncol 23: Suppl 8: 69–77

    PubMed  CAS  Google Scholar 

  • Van Kooten B, Van Diemen HA, Groenhout KM et al. (1992) A pilot study on the influence of a corticotropin (4–9) analogue on vinca alkaloid-induced neuropathy. Arch Neurol 49: 1027–1031

    PubMed  Google Scholar 

  • Venturini M, Michelotti A, Del Mastro L et al. (1996) Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane vs. no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer. J Clin Oncol 14: 3112–3120

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. B. Weiss
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H.-P. Lipp
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. T. Hartmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C. Bokemeyer
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M. Sökler
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Abteilung Innere Medizin II Hämatologie, Onkologie, Immunologie und Rheumatologie, Universitätsklinikum Tübingen, Otfried-Müller-Straße 10, 72076, Tübingen, Deutschland

    C. Bokemeyer

  2. Universitätsapotheke Tübingen, Röntgenweg 9, 72076, Tübingen, Deutschland

    H.-P. Lipp

Rights and permissions

Reprints and permissions

Copyright information

© 1998 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Weiss, B., Lipp, HP., Hartmann, J.T., Bokemeyer, C., Sökler, M. (1998). Prophylaxe und Behandlung spezieller Nebenwirkungen von Zytostatika. In: Bokemeyer, C., Lipp, HP. (eds) Praktische Aspekte der supportiven Therapie in Hämatologie und Onkologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-80459-5_8

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-80459-5_8

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-63335-8

  • Online ISBN: 978-3-642-80459-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation